Back to Search
Start Over
Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
- Source :
- PR Newswire. February 6, 2018
- Publication Year :
- 2018
-
Abstract
- - Topline results from ACHIEVE I (UBR-MD-01) study demonstrate efficacy, safety and tolerability - - Study meets Co-Primary Endpoints in First of Two Phase 3 Studies - DUBLIN, Feb. 6, [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PR Newswire
- Publication Type :
- News
- Accession number :
- edsgcl.526438158